Site icon pharmaceutical daily

Global Diabetic Neuropathic Pain Market Report to 2031: Players Include AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly and GlaxoSmithKline – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Diabetic Neuropathic Pain Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the diabetic neuropathic pain market through 2031.

Diabetic neuropathic pain (DNP) is clinically defined as pain resulting from peripheral, autonomic, focal, or proximal nerve damage in patients with diabetes mellitus (DM). It most commonly manifests distally to affect the hands and feet and can occur in patients with either a type 1 diabetes (T1D) or type 2 diabetes (T2D) diagnosis. Symptoms vary from tingling, burning, sharp, shooting, or lancinating pain.

Growth in the DNP market is expected to be driven by the potential introduction of four promising late-stage pipeline products into the market during the forecast period, some of which are directed towards significant unmet needs

Companies Mentioned

Key Highlights

Scope

Reasons to Buy

Key Topics Covered:

1 Diabetic Neuropathic Pain: Executive Summary

2 Introduction

3 Disease Overview

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities

4.3 Global and historical trends

4.4 7MM forecast methodology

4.4.1 Sources used

4.4.2 Forecast assumptions and methods

4.4.3 Total prevalent cases of DNP

4.4.4 Diagnosed prevalent cases of DNP

4.4.5 Diagnosed prevalent cases of DNP by DSPN and non-DSPN

4.4.6 p-DPN among diagnosed prevalent cases of T1D and T2D

4.5 Epidemiological forecast for total prevalent cases of DNP (2021-31)

4.5.1 Total prevalent cases of DNP

4.5.2 Age-specific total prevalent cases of DNP

4.5.3 Sex-specific total prevalent cases of DNP

4.5.4 Diagnosed prevalent cases of DNP

4.5.5 Diagnosed prevalent cases of DNP by DSPN and Non-DSPN

4.5.6 p-DPN among diagnosed prevalent cases of T1D and T2D

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 COVID-19 impact

4.6.3 Limitations of the analysis

4.6.4 Strengths of the analysis

5 Disease Management

5.1 Diagnosis overview

5.2 Treatment overview

5.3 Other KOL insights on disease management

6 Competitive Assessment

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Development of therapies with an improved efficacy profile

7.3 Development of therapies with improved safety and tolerability profile

7.4 Development of a curative or disease-modifying agent

7.5 Improving physician and public recognition of DNP

8 R&D Strategies

8.1 Overview

8.1.1 Development of analgesics with novel MOAs

8.1.2 Patient stratification

8.2 Clinical trials design

8.2.1 Clinical endpoints

8.2.2 High failure rate in DNP clinical trials

8.2.3 Patient recruitment

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-making trends

12 Market Outlook

13 Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/y76znp

Source: GlobalData

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version